SCHEMBL23675446

SCHEMBL23675446

O=C(NCc1ccc(Cl)cc1)c1cc(Cl)ccc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB P07437 2/20 0.72
P2RX1 P51575 3/20 0.68
TMPRSS4 Q9NRS4 2/20 0.68
POLA1 P09884 2/20 0.64
CDK1 P06493 1/20 0.61
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
HPGD P15428 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
HSP90AA1 P07900 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
KCNMA1 Q12791 1/20 0.55
P2RX4 Q99571 1/20 0.54
P2RX7 Q99572 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26097052 0.91 HPGD (0.63) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL13812639 0.91 P2RX1 (0.66) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL30100461 0.91 TUBB (0.75) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL13236587 0.91 TUBB (0.75) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL4019571 0.90 TUBB (0.63) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL13812818 0.89 TUBB (0.69) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL18341428 0.87 TMPRSS4 (0.81) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL26098397 0.87 P2RX1 (0.64) TUBBP2RX1TMPRSS4POLA1CDK1
SCHEMBL26098852 0.86 CYP1A2 (0.63) TUBBP2RX1TMPRSS4CA1CA2
SCHEMBL23675443 0.86 P2RX1 (0.64) TUBBP2RX1TMPRSS4POLA1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE TUBB 3158/4885P2RX1 3088/4885TMPRSS4 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.